نتائج البحث - Joan T. Merrill

تنقيح النتائج
  1. 1
    SARS-CoV-2 vaccines in patients with SLE

    SARS-CoV-2 vaccines in patients with SLE حسب Wei Tang, Anca Askanase, Leila Khalili, Joan T. Merrill

    منشور في 2021
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications

    Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications حسب Joan T. Merrill, Doruk Erkan, Jerald Winakur, Judith A. James

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Which outcome measures in SLE clinical trials best reflect medical judgment?

    Which outcome measures in SLE clinical trials best reflect medical judgment? حسب Aikaterini Thanou, Eliza F. Chakravarty, Judith A. James, Joan T. Merrill

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    TAM receptor ligands in lupus: Protein S but not Gas6 levels reflect disease activity in systemic lupus erythematosus

    TAM receptor ligands in lupus: Protein S but not Gas6 levels reflect disease activity in systemic lupus erythematosus حسب Chang‐Hee Suh, Brendan Hilliard, Sophia Li, Joan T. Merrill, Philip L. Cohen

    منشور في 2010
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Circulating levels of soluble MER in lupus reflect M2c activation of monocytes/macrophages, autoantibody specificities and disease activity

    Circulating levels of soluble MER in lupus reflect M2c activation of monocytes/macrophages, autoantibody specificities and disease activity حسب Gaetano Zizzo, Justus Guerrieri, Lindsay M Dittman, Joan T. Merrill, Philip L. Cohen

    منشور في 2013
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Anti-b 2 -Glycoprotein I and Antiphosphatidylserine Antibodies Are Predictors of Arterial Thrombosis in Patients With Antiphospholipid Syndrome

    Anti-b 2 -Glycoprotein I and Antiphosphatidylserine Antibodies Are Predictors of Arterial Thrombosis in Patients With Antiphospholipid Syndrome حسب Luis R. Lopez, Ken J. Dier, Daniel Lopez, Joan T. Merrill, Catherine Fink

    منشور في 2004
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    The genetics of systemic lupus erythematosus and implications for targeted therapy

    The genetics of systemic lupus erythematosus and implications for targeted therapy حسب AL Sestak, Barbara G. Fürnrohr, John B. Harley, Joan T. Merrill, Bahram Namjou

    منشور في 2011
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    SAT0240 Phase 3 trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE)

    SAT0240 Phase 3 trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE) حسب Joan T. Merrill, RS Martin, WR Shanahan, Morton Scheinberg, Kenneth Kalunian, David Wofsy

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial

    Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-b... حسب Joan T. Merrill, William Shanahan, Morton Scheinberg, Kenneth Kalunian, David Wofsy, Renée S. Martin

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Impact of heart rate variability, a marker for cardiac health, on lupus disease activity

    Impact of heart rate variability, a marker for cardiac health, on lupus disease activity حسب Aikaterini Thanou, Stavros Stavrakis, John Dyer, Melissa E. Munroe, Judith A. James, Joan T. Merrill

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Tissue factor upregulation is associated with SARS‐CoV‐2 in the lungs of COVID‐19 patients

    Tissue factor upregulation is associated with SARS‐CoV‐2 in the lungs of COVID‐19 patients حسب Sandeep Subrahmanian, Alain Borczuk, Steven Salvatore, Kar‐Ming Fung, Joan T. Merrill, Jeffrey Laurence, Jasimuddin Ahamed

    منشور في 2021
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Genome-wide DNA methylation patterns in CD4+ T cells from patients with systemic lupus erythematosus

    Genome-wide DNA methylation patterns in CD4+ T cells from patients with systemic lupus erythematosus حسب Matlock A. Jeffries, Mikhail G. Dozmorov, Yuhong Tang, Joan T. Merrill, Jonathan D. Wren, Amr H. Sawalha

    منشور في 2011
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Proinflammatory Adaptive Cytokine and Shed Tumor Necrosis Factor Receptor Levels Are Elevated Preceding Systemic Lupus Erythematosus Disease Flare

    Proinflammatory Adaptive Cytokine and Shed Tumor Necrosis Factor Receptor Levels Are Elevated Preceding Systemic Lupus Erythematosus Disease Flare حسب Melissa E. Munroe, Evan S. Vista, Joel M. Guthridge, Linda F. Thompson, Joan T. Merrill, Judith A. James

    منشور في 2014
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus

    Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus حسب Joan T. Merrill, Daniel J. Wallace, Stephen Wax, Amy Kao, Patricia A. Fraser, Peter Chang, David Isenberg

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study

    Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study حسب William Stohl, Joan T. Merrill, James D. McKay, Jeffrey Lisse, Z. John Zhong, William W. Freimuth, Mark C. Genovese

    منشور في 2013
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    Antiglutamate Receptor Antibodies and Cognitive Impairment in Primary Antiphospholipid Syndrome and Systemic Lupus Erythematosus

    Antiglutamate Receptor Antibodies and Cognitive Impairment in Primary Antiphospholipid Syndrome and Systemic Lupus Erythematosus حسب Maria Gerosa, Barbara Poletti, Francesca Pregnolato, G. Castellino, Annalisa Lafronza, Vincenzo Silani, Piersandro Riboldi, Pier Luigi Meroni, Joan T. Merrill

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus

    Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus حسب Joan T. Merrill, Richard Furie, Victoria P. Werth, Munther A. Khamashta, Jörn Drappa, Xue Wang, Gabor G. Illei, Raj Tummala

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    DNA methylation patterns in naïve CD4+ T cells identify epigenetic susceptibility loci for malar rash and discoid rash in systemic lupus erythematosus

    DNA methylation patterns in naïve CD4+ T cells identify epigenetic susceptibility loci for malar rash and discoid rash in systemic lupus erythematosus حسب Paul Renauer, Patrick Coit, Matlock A. Jeffries, Joan T. Merrill, W. Joseph McCune, Kathleen Maksimowicz‐McKinnon, Amr H. Sawalha

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    Renal involvement in lupus is characterized by unique DNA methylation changes in naïve CD4+ T cells

    Renal involvement in lupus is characterized by unique DNA methylation changes in naïve CD4+ T cells حسب Patrick Coit, Paul Renauer, Matlock A. Jeffries, Joan T. Merrill, W. Joseph McCune, Kathleen Maksimowicz‐McKinnon, Amr H. Sawalha

    منشور في 2015
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study

    Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study حسب Munther A. Khamashta, Joan T. Merrill, Victoria P. Werth, Richard Furie, Kenneth Kalunian, Gabor G. Illei, Jörn Drappa, Xue Wang, Warren Greth

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: